Manuscripts

Search by keyword, year, or author name.

Showing 1552 manuscripts.

Dose proportional inhibition of HIV-1 replication by mycophenolic acid and synergistic inhibition in combination with abacavir, didanosine, and tenofovir

Mohammed M. Hossain, Jason J. Coull, George Drusano, David M. Margolis. Dose proportional inhibition of HIV-1 replication by mycophenolic acid and synergistic inhibition in combination with abacavir, didanosine, and tenofovir. Antiviral Research. 2002. 55: 41-52.

Year

2002

Journal

Antiviral Research

Adherence to HAART among patients with HIV: breakthroughs and barriers

Jeannette Ickovics, C.S. Meade. Adherence to HAART among patients with HIV: breakthroughs and barriers. AIDS Care. 2002. 14: 309-18.

Year

2002

Journal

AIDS Care

CD4 response is correlated with peak plasma concentrations of indinavir in adults with undetectable human immunodeficiency virus ribonucleic acid

Peter Anderson, Richard Brundage, Thomas N Kakuda, Courtney V. Fletcher. CD4 response is correlated with peak plasma concentrations of indinavir in adults with undetectable human immunodeficiency virus ribonucleic acid. Clinical Pharmacology & Therapeutics. 2002. 71: 280-5.

Year

2002

Journal

Clinical Pharmacology & Therapeutics

Modelling HIV viral rebound using non-linear mixed effects models

A. P. Fitzgerald, Victor DeGruttola, Florin Vaida. Modelling HIV viral rebound using non-linear mixed effects models. Statistics In Medicine. 2002. 21: 2093-108.

Year

2002

Journal

Statistics In Medicine

Population pharmacokinetics of dapsone in children with human immunodeficiency virus infection.

Mark Mirochnick, Ellen Rae Cooper, Edmund Capparelli, Kenneth McIntosh, Jane C. Lindsey, Jing Xu, David P. Jacobus, Lynne M. Mofenson, Vincent R. Bonagura, Sharon Appelbaum Nachman, Ram Yogev, John L. Sullivan, Stephen A. Spector. Population pharmacokinetics of dapsone in children with human immunodeficiency virus infection.. Clinical Pharmacology & Therapeutics. 2001. 70: 24-32.

Year

2001

Journal

Clinical Pharmacology & Therapeutics

Pharmacokinetics of nelfinavir in human immunodeficiency virus-infected infants.

Edmund Capparelli, John L. Sullivan, Lynne M. Mofenson, Elaine Margaret Smith, Bobbie L. Graham, Bobbie L. Graham, Paula Britto, Mark I. Becker, Diane Holland, James D. Connor, Katherine Luzuriaga. Pharmacokinetics of nelfinavir in human immunodeficiency virus-infected infants.. Pediatric Infectious Disease Journal. 2001. 20: 746-51.

Year

2001

Journal

Pediatric Infectious Disease Journal

Human Immunodeficiency Virus type 1 (HIV-1) gp120-specific antibodies in neonates receiving an HIV-1 recombinant gp120 vaccine.

Sandra K. Burchett, Lisa M. Frenkel, Elizabeth (Betsy) J. McFarland, Ram Yogev, William Borkowsky, Francis Gigliotti, Terence Fenton, Katherine Luzuriaga, Diane W. Wara, Robert Livingston, James McNamara, Pearl Samson, Minhee Kang, Lynne M. Mofenson, Coleen K. Cunningham, Anne-Marie Duliege, Faruk Sinangil, Stephen A. Spector, Eleanor Jimenez, Yvonne J. Bryson. Human Immunodeficiency Virus type 1 (HIV-1) gp120-specific antibodies in neonates receiving an HIV-1 recombinant gp120 vaccine.. Journal of Infectious Diseases. 2001. 184: 1331-1335.

Year

2001

Journal

Journal of Infectious Diseases

Effect of combination therapy including protease inhibitors on mortality among children and adolescents infected with HIV-1.

Steven Gortmaker, Michael Hughes, Joseph S. Cervia, Rebecca Oyomopito, Michael T. Brady, James M. Oleske, George M. Johnson, George Seage, Lin-Ye Song, Wayne M. Dankner, Wayne M. Dankner, James M. Oleske. Effect of combination therapy including protease inhibitors on mortality among children and adolescents infected with HIV-1.. New England Journal of Medicine. 2001. 21: 1522-1528. PMID: 11794218

Year

2001

Journal

New England Journal of Medicine

ACTG (AIDS Clinical Trials Group) 384: A strategy trial comparing consecutive treatments for HIV-1

Laura Smeaton, Victor DeGruttola, Gregory K. Robbins, Robert Shafer. ACTG (AIDS Clinical Trials Group) 384: A strategy trial comparing consecutive treatments for HIV-1. Controlled Clinical Trials. 2001. 22: 142-59.

Year

2001

Journal

Controlled Clinical Trials

Effect of IL-2 therapy on plasma hepatitis C virus-RNA levels in HIV/hepatitis C virus co-infected patients

Hernan Valdez, Julia A. Metcalf, Barbara Gripshover, Jeffrey M. Jacobson, Ronald T. Mitsuyasu, Michael M. Lederman. Effect of IL-2 therapy on plasma hepatitis C virus-RNA levels in HIV/hepatitis C virus co-infected patients. AIDS. 2001. 15: 661-2.

Year

2001

Journal

AIDS